JP2013529080A5 - - Google Patents

Download PDF

Info

Publication number
JP2013529080A5
JP2013529080A5 JP2013510643A JP2013510643A JP2013529080A5 JP 2013529080 A5 JP2013529080 A5 JP 2013529080A5 JP 2013510643 A JP2013510643 A JP 2013510643A JP 2013510643 A JP2013510643 A JP 2013510643A JP 2013529080 A5 JP2013529080 A5 JP 2013529080A5
Authority
JP
Japan
Prior art keywords
dom7h
seq
variant
variable domain
single variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013510643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013529080A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/058298 external-priority patent/WO2011144751A1/en
Publication of JP2013529080A publication Critical patent/JP2013529080A/ja
Publication of JP2013529080A5 publication Critical patent/JP2013529080A5/ja
Pending legal-status Critical Current

Links

JP2013510643A 2010-05-20 2011-05-20 改良された抗血清アルブミン結合変異体 Pending JP2013529080A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34651910P 2010-05-20 2010-05-20
US61/346,519 2010-05-20
PCT/EP2011/058298 WO2011144751A1 (en) 2010-05-20 2011-05-20 Improved anti-serum albumin binding variants

Publications (2)

Publication Number Publication Date
JP2013529080A JP2013529080A (ja) 2013-07-18
JP2013529080A5 true JP2013529080A5 (enExample) 2014-07-03

Family

ID=44352234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013510643A Pending JP2013529080A (ja) 2010-05-20 2011-05-20 改良された抗血清アルブミン結合変異体

Country Status (13)

Country Link
US (2) US9040668B2 (enExample)
EP (1) EP2571900A1 (enExample)
JP (1) JP2013529080A (enExample)
KR (1) KR20130109977A (enExample)
CN (1) CN103003303A (enExample)
AU (1) AU2011254559B2 (enExample)
BR (1) BR112012029280A2 (enExample)
CA (1) CA2799633A1 (enExample)
EA (1) EA201291009A1 (enExample)
IL (1) IL222802A0 (enExample)
MX (1) MX2012013406A (enExample)
SG (1) SG185437A1 (enExample)
WO (1) WO2011144751A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
RU2652783C2 (ru) 2012-12-21 2018-05-03 Санофи Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
EP3974449A1 (en) * 2015-11-13 2022-03-30 Ablynx NV Improved serum albumin-binding immunoglobulin variable domains
CN115837014A (zh) 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
WO2025021183A1 (zh) * 2023-07-27 2025-01-30 上海复宏汉霖生物医药有限公司 编码促肾上腺皮质激素的多核苷酸及其相关组合物和方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
EP1737962B1 (en) 2004-03-24 2010-09-01 Domantis Limited Gas1 universal leader
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
BRPI0518761A2 (pt) 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
AU2008259590A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
US8877186B2 (en) * 2007-06-06 2014-11-04 Domantis Limited Polypeptides, antibody variable domains and antagonists
BRPI0819693A2 (pt) 2007-11-30 2020-08-18 Glaxo Group Limited Construção de ligação de antígeno, método para tratar um paciente que sofre de câncer ou uma doença inflamatória, sequência de polinucleotídeo, polinucleotídeo, célula hospedeira transformada ou transfectada recombinante, método para produziruma construção de ligação de antígeno, e, composição farmacêutica
WO2010094722A2 (en) * 2009-02-19 2010-08-26 Glaxo Group Limited Improved anti-serum albumin binding variants
WO2010094723A2 (en) * 2009-02-19 2010-08-26 Glaxo Group Limited Improved anti-serum albumin binding variants
KR20110119806A (ko) 2009-02-19 2011-11-02 글락소 그룹 리미티드 개선된 항­tnfr1 폴리펩티드,항체 가변 도메인 및 길항제
JP2012521971A (ja) * 2009-03-27 2012-09-20 グラクソ グループ リミテッド 薬物融合体および複合体
JP2012532619A (ja) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド Tnfr1を部分的に阻害するためのアンタゴニスト、用途および方法
CN104147611A (zh) * 2009-09-30 2014-11-19 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物

Similar Documents

Publication Publication Date Title
JP2013529080A5 (enExample)
JP2023027258A (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
CN110049997B (zh) 改进的血清白蛋白结合免疫球蛋白单可变结构域
CN110191896B (zh) 改进的血清白蛋白结合物
CN103619878B (zh) 结合血清白蛋白的蛋白
JP2009545319A5 (enExample)
JP2013538566A5 (enExample)
JP2017506075A5 (enExample)
JP2017527272A5 (enExample)
JP6333271B2 (ja) IL−1βへの結合メンバー
JP2014513953A5 (enExample)
IL267897B2 (en) Improved serum albumin binders
JP2010502183A5 (enExample)
JP2017500018A5 (enExample)
CN108473564A (zh) 改进的血清白蛋白结合剂
JP2018526989A5 (enExample)
JP2009539349A5 (enExample)
CN102781959A (zh) 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
JP2010533498A5 (enExample)
JP2020521458A5 (enExample)
JP2010535032A5 (enExample)
JP2009528828A5 (enExample)
EA034854B1 (ru) Анти-il-17-антитела, способ их получения и способ применения
JP2013543384A5 (enExample)
JP2015506945A5 (enExample)